Current Reviews in Clinical and Experimental Pharmacology

Scope & Guideline

Exploring Innovations in Clinical and Experimental Pharmacology

Introduction

Welcome to your portal for understanding Current Reviews in Clinical and Experimental Pharmacology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2772-4328
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2021 to 2024
AbbreviationCURR REV CLIN EXP PH / Curr. Rev. Clin. Exper. Pharmacol.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

Current Reviews in Clinical and Experimental Pharmacology is dedicated to providing comprehensive reviews and analyses of current research in pharmacology, with a strong emphasis on clinical applications and translational medicine. The journal aims to bridge the gap between laboratory-based research and clinical practice, addressing significant issues in drug development, pharmacotherapy, and the safety and efficacy of medications.
  1. Clinical Pharmacology and Therapeutics:
    The journal focuses on the effects, safety, and efficacy of drugs in clinical settings, providing insights into therapeutic interventions and management of various diseases.
  2. Translational Research:
    It emphasizes the importance of translating laboratory findings into clinical applications, exploring new therapeutic targets, drug mechanisms, and treatment strategies.
  3. Systematic Reviews and Meta-Analyses:
    The journal frequently publishes systematic reviews and meta-analyses to synthesize evidence regarding pharmacological treatments and interventions, aiding in clinical decision-making.
  4. Emerging Therapies and Novel Drug Development:
    Current Reviews highlights innovative drug formulations, repurposing existing medications, and the exploration of alternative therapies such as natural compounds and nutraceuticals.
  5. Preclinical and Experimental Models:
    The journal discusses preclinical studies and experimental models that are crucial for understanding drug mechanisms and testing new therapeutic approaches.
The journal has seen a significant evolution in its thematic focus, with several emerging trends that reflect contemporary challenges and advancements in pharmacology and therapeutics. These trends highlight the journal's responsiveness to the changing landscape of medical research and clinical needs.
  1. Integrative and Multidisciplinary Approaches:
    There is a growing trend towards integrative studies that combine pharmacology with other disciplines, such as genomics, proteomics, and systems biology, to enhance therapeutic efficacy.
  2. Natural Products and Herbal Medicine:
    Recent publications have increasingly highlighted the role of natural products and herbal compounds in pharmacotherapy, reflecting a renewed interest in alternative and complementary medicines.
  3. Patient-Centric Research:
    Emerging themes emphasize the importance of patient perspectives, adherence, and individualized treatment strategies, aligning with the broader movement towards patient-centered care.
  4. Advanced Therapeutic Modalities:
    The journal is increasingly publishing research on advanced therapeutic modalities, such as gene therapy, cell therapy, and nanotechnology, indicating a shift towards innovative treatment options.
  5. Drug Repurposing and Safety Profiles:
    There is a notable increase in studies focusing on drug repurposing strategies and the safety profiles of existing medications, particularly in the context of emerging health crises like the COVID-19 pandemic.

Declining or Waning

Over the years, certain themes within the journal have begun to lose prominence, reflecting shifts in research focus and evolving priorities in pharmacology and clinical practice. This decline may indicate changing trends in drug development, therapeutic approaches, and clinical research methodologies.
  1. Traditional Pharmacotherapy:
    There appears to be a waning interest in traditional pharmacotherapy approaches without innovative angles, as more research is focused on novel therapies and drug repurposing.
  2. Single-Agent Drug Studies:
    Research that solely focuses on the efficacy of single-agent drugs without considering combination therapies or multi-target approaches is becoming less common.
  3. Historical Reviews of Established Drugs:
    While historical reviews of established drugs were once prevalent, there is now a shift towards investigating new compounds and their potential applications.
  4. Pharmacokinetics in Stable Populations:
    Studies focusing on pharmacokinetics in stable populations are declining as the journal shifts towards more dynamic and complex patient populations, including those with comorbidities.
  5. Basic Science without Clinical Relevance:
    Research that emphasizes basic science without a clear pathway to clinical application is becoming less favored in favor of studies with direct clinical implications.

Similar Journals

Journal of Pharmacy & Pharmacognosy Research

Connecting Researchers in the World of Pharmacy
Publisher: JOURNAL PHARMACY & PHARMACOGNOSY RESEARCH-JPPRESISSN: 0719-4250Frequency: 6 issues/year

Journal of Pharmacy & Pharmacognosy Research, published by JOURNAL PHARMACY & PHARMACOGNOSY RESEARCH-JPPRES, is a prominent open-access journal established in 2013, headquartered in Antofagasta, Chile. With a focus on the fields of Complementary and Alternative Medicine, Drug Discovery, Pharmaceutical Science, Pharmacology, and Pharmacy, this journal is recognized for its commitment to advancing research and disseminating knowledge within these important areas. With a current impact factor that reflects its academic rigor and relevance, the journal has achieved substantial recognition, evident by its Q2 and Q3 quartile rankings in multiple categories, indicating its growing influence on the scientific community. The Scopus rankings further highlight its standing in pharmacy and pharmacological disciplines, providing a valuable platform for researchers, professionals, and students to share their findings and insights. With its open access model, the journal ensures that high-quality research is available to a global audience, paving the way for collaborative advancements in pharmaceutical sciences.

Expert Opinion on Drug Metabolism & Toxicology

Transforming Knowledge into Practice in Toxicology
Publisher: TAYLOR & FRANCIS LTDISSN: 1742-5255Frequency: 12 issues/year

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Empowering healthcare through innovative pharmacological research.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

INDIAN JOURNAL OF PHARMACOLOGY

Empowering researchers with cutting-edge pharmacological discoveries.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

INVESTIGATIONAL NEW DRUGS

Pioneering Innovations in Drug Development
Publisher: SPRINGERISSN: 0167-6997Frequency: 6 issues/year

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

Drug Target Insights

Advancing the Future of Pharmacology and Drug Discovery.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

Pakistan Journal of Pharmaceutical Sciences

Delivering critical studies that shape the pharmaceutical landscape.
Publisher: UNIV KARACHIISSN: 1011-601XFrequency: 4 issues/year

Pakistan Journal of Pharmaceutical Sciences, published by the University of Karachi, serves as a vital platform for advancing research in the field of pharmaceutical sciences. With a strong commitment to disseminating innovative findings and critical studies since its inception in 1995, the journal focuses on a wide array of topics including pharmacology, toxicology, and pharmaceutics. With an ISSN of 1011-601X, it holds a reputable position within the academic community, reflecting its Q3 category ranking in Pharmaceutical Science as of 2023. While the journal is currently not designated as Open Access, it remains accessible through institutional subscriptions, ensuring that both emerging and established researchers can contribute to and benefit from its scholarly content. This publication not only promotes scientific dialogue but also aims to bridge the gap between academia and industry, appealing to a diverse audience of researchers, professionals, and students seeking to stay informed about the latest advancements and trends in pharmaceutical research.

AMERICAN JOURNAL OF THERAPEUTICS

Transforming Patient Care with Cutting-Edge Insights
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1075-2765Frequency: 6 issues/year

The American Journal of Therapeutics is a prominent academic journal published by Lippincott Williams & Wilkins, specializing in the fields of medicine and pharmacology. With a rich history originating from 1960 and a commitment to advancing therapeutic knowledge through peer-reviewed research, this journal serves as a vital resource for professionals, researchers, and students alike. Its strong impact factor, alongside its classification in the Q2 and Q3 quartiles for diverse categories in medicine and pharmacology, underscores its significance in the academic community. The journal engages with the latest findings and innovations in therapeutic approaches, offering a platform for discussion and dissemination of research that addresses critical healthcare challenges. Although it operates under a traditional subscription model, the journal aims to foster open discourse within the therapeutic landscape, making it essential reading for those dedicated to enhancing patient care and pharmaceutical practices.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Advancing therapeutic knowledge for a healthier tomorrow.
Publisher: ELSEVIER SCIENCE INCISSN: 0011-393XFrequency: 2 issues/year

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Shaping the Future of Therapeutics Through Rigorous Inquiry
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0022-3565Frequency: 12 issues/year

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.